Cell Therapeutics Announces Promising Results for Anti-Cancer Drug CT-2584

Strategic Insights -

In a recent presentation at the 34th Annual Meeting of the American Society of Clinical Oncology, Cell Therapeutics, Inc. revealed encouraging data from a Phase I clinical trial of its novel anti-cancer drug, CT-2584. The study, conducted at the Memorial Sloan-Kettering Cancer Center in New York City, aimed to establish a maximum tolerated dose, develop a pharmacokinetic profile, and evaluate the anti-tumor effect of CT-2584. Preliminary results show that 27% of patients experienced tumor stabilization, with 10 patients (29%) still alive after a median of 10 months following treatment.

Key Takeaways:

  • The Phase I clinical trial of CT-2584, a small-molecule anti-cancer drug, demonstrated a tolerability profile that enables chronic, longer-term outpatient therapy.
  • Of the 18 patients evaluable for tumor response, 13 remain alive at a median of eight months out from treatment with CT-2584.
  • In the companion trial conducted at Christie Hospital in Manchester, England, 10 (29%) of the 35 evaluable patients experienced tumor stabilization, and seven are still alive after a median of 10 months.
  • The company plans to begin Phase II trials this year in advanced prostate cancer and in advanced sarcomas, citing CT-2584's potent anti-angiogenic effects.
  • The unique mechanism of action of CT-2584 involves its effect on tumor-cell phospholipids, such as phosphatidic acid, which plays a role in neoplastic cell transformation.
  • In preclinical studies, CT-2584 was effective in vitro against a broad array of tumor cell types, including those resistant to multiple kinds of chemotherapy drugs.

Statistics:

  • 23 patients have been enrolled in the United States, with 18 evaluable for tumor response.
  • 27% of patients experienced tumor stabilization (5 out of 18 patients).
  • 29% of patients (10 out of 35 evaluable patients) experienced tumor stabilization in the companion trial conducted at Christie Hospital.
  • 21 out of 35 evaluable patients in both trials are still alive a median of 10 months after starting treatment with CT-2584.
  • Preclinical studies demonstrated CT-2584's effectiveness in vitro against a broad array of tumor cell types, with activity observed at drug levels below which cancer-cell killing was observed.

Sources:

  • Cell Therapeutics, Inc.
  • American Society of Clinical Oncology
  • Memorial Sloan-Kettering Cancer Center
  • Christie Hospital